I’ve once tried to obtained the Pediatric Nursing Certification Board (PNCB) certification as I believed it would be a valuable addition to my professional development but vaguely remember the process. I believe it was during the pandemic, and it just wasn’t a priority but I may decide to revisit it, plus their website is more organized. This could also be a great certification for people who have little to no experience with kids, other providers i.e. FNPs, or to simply strengthen your foundation in pediatric psychiatric care (information at the bottom). Here’s a review of some of the information that was provided and helpful:

ADHD MEDICATION SAFETY AND MANAGEMENT

The safety profile of ADHD medications can be evaluated by 5 parameters:

1. FDA-approved indications
2. Number of years the medication has been on the market
3. Potential for harm from overdose
4. U.S. boxed warnings
5. Known potentially harmful long-term effects

For preschool-aged children with ADHD, the initial management is behavioral interventions such as parental management training and parent-child interaction therapy, usually for a period of 10 to 20 weeks. If these do not produce sufficient improvement, methylphenidate may be used as the first pharmacologic intervention. Although this use is off-label because it is outside FDA indications, the Preschool ADHD Treatment Study demonstrated safety and efficacy of immediate-release methylphenidate in children ages 3 to 5.

Immediate-release methylphenidate is available as an oral solution (5 mg/5 mL) and chewable tablets (2.5 mg, 5 mg, 10 mg). Many preschoolers cannot swallow intact tablets, and tablet strengths may exceed recommended doses for this age group. Extended-release methylphenidate is available in liquid, chewable tablet, and orally dissolving tablet formulations, with the last approved by the FDA in 2017.

Lisdexamfetamine has a lower abuse potential than other amphetamines because it requires gastrointestinal absorption and enzymatic cleavage to become active, making it ineffective if taken intranasally or intravenously.

Amphetamines are contraindicated in children with hyperthyroidism, moderate to severe hypertension, and symptomatic cardiovascular disease. Other contraindications include glaucoma, history of substance abuse, hypersensitivity to sympathomimetic amines, and use of monoamine oxidase inhibitors within the past two weeks. They are not contraindicated in asthma, since amphetamines produce a weak bronchodilatory response, and not in renal impairment, although decreased elimination may occur. Serious cardiovascular events have been reported in children with structural abnormalities, significant rhythm disturbances, or cardiomyopathy.

Medication interactions are another important consideration. Vitamin C (ascorbic acid) can decrease amphetamine blood levels, while calcium carbonate (Tums) and sodium bicarbonate can increase blood levels. These alkalinizing agents are widely available over the counter and are often used without medical supervision for symptoms such as reflux or dyspepsia.

Guanfacine is an alpha2A-adrenergic agonist available in immediate-release (IR) and extended-release (ER) formulations. It is not a controlled substance and works by reducing sympathetic nerve impulses, thereby lowering vasomotor tone and heart rate. It also improves ADHD symptoms by enhancing receptor activity in the prefrontal cortex. Blood pressure and heart rate monitoring is recommended for children taking guanfacine. ER guanfacine (Intuniv) is FDA-approved for monotherapy or adjunctive therapy in children ages 6 through 17. The ER and IR formulations cannot be substituted on a milligram-per-milligram basis because of their different pharmacokinetic profiles. If changing from IR to ER, the IR must be discontinued, and the ER started with titration to effect.

• The ER preparation of guanfacine produces a relatively lower peak level and may cause fewer or less intense adverse effects than the IR preparation. The FDA label instructs that heart rate and blood pressure be measured before initiation, after dose increases, and periodically during treatment, with more frequent checks for patients at risk of hypotension, bradycardia, or cardiovascular disease. No laboratory monitoring is required. Patient and caregiver education is essential: tablets should be swallowed whole and not crushed, chewed, or broken, since this can alter release, and guanfacine ER should not be taken with high-fat meals because this can increase blood levels. There are no restrictions on timing with meals, liquids, or antacids.
• Drug interactions are important when prescribing guanfacine. Strong CYP3A4 inhibitors such as clarithromycin, ketoconazole, and nefazodone significantly increase serum levels, while moderate inhibitors such as doxycycline, fluvoxamine, and grapefruit juice also have an effect, though to a lesser extent. The manufacturer recommends reducing the guanfacine ER dose by 50% when combined with strong or moderate CYP3A4 inhibitors. Not all macrolide antibiotics have the same effects; for example, azithromycin does not inhibit CYP3A4.

Clonidine is another alpha2-adrenergic agonist used for ADHD. Extended-release clonidine (Kapvay and generic) is FDA-approved as monotherapy or adjunctive therapy with stimulants in children and adolescents. It is available in 0.1 mg and 0.2 mg tablets. The recommended starting dose is 0.1 mg at bedtime, with titration in 0.1 mg increments weekly to a maximum of 0.4 mg per day. Doses exceeding 0.1 mg daily should be divided into two doses, with the larger dose at bedtime. Immediate-release clonidine is not FDA-approved for pediatric ADHD but is sometimes used off-label, starting at 0.05 mg daily and titrated as needed, up to 0.4 mg daily. Sudden discontinuation of clonidine should be avoided, as it can cause severe rebound hypertension. Gradual tapering by 0.1 mg every three to seven days is recommended.

Atomoxetine (Strattera) is a selective norepinephrine reuptake inhibitor approved for children ages six and older. It was first approved in 2002, and generic formulations became available in 2017. Contraindications include hypersensitivity to the drug or its components, narrow-angle glaucoma, pheochromocytoma or history of pheochromocytoma, use of monoamine oxidase inhibitors within the past two weeks, and severe cardiovascular conditions that may worsen with increases in heart rate or blood pressure. Atomoxetine has been associated with clinically significant increases of 15 to 20 mm Hg in blood pressure and 20 beats per minute in heart rate.

• Atomoxetine is metabolized through the CYP2D6 pathway. Strong CYP2D6 inhibitors or poor metabolizer status may necessitate dose adjustments but are not absolute contraindications. Unlike some medications, neither Wilms’ tumor nor kidney disease are contraindications to atomoxetine use.

KEY SUMMARY

• ADHD medication safety is assessed by FDA indications, years on the market, overdose risk, boxed warnings, and long-term effects.
• Preschool ADHD treatment begins with behavioral therapy; methylphenidate may be used off-label if needed.
• Methylphenidate has both IR and ER formulations, with dosing challenges in preschoolers.
• Lisdexamfetamine has lower abuse potential due to GI activation.
• Amphetamine contraindications include hyperthyroidism, hypertension, cardiovascular disease, glaucoma, substance abuse history, and MAOI use. Asthma and renal impairment are not contraindications.
• Drug interactions with amphetamines: Vitamin C lowers levels, while calcium carbonate and sodium bicarbonate increase them.
• Guanfacine ER is FDA-approved for children 6–17, requires BP/HR monitoring, cannot be substituted for IR, and should not be taken with high-fat meals. Levels are increased by CYP3A4 inhibitors, requiring dose reduction.
• Clonidine ER is FDA-approved for ADHD, with doses titrated up to 0.4 mg daily. IR clonidine is off-label. Both require tapering to avoid rebound hypertension.
• Atomoxetine is FDA-approved for children over six. Contraindications include glaucoma, pheochromocytoma, MAOI use, and severe cardiovascular disease. It may raise BP and HR, is metabolized via CYP2D6, and requires dose adjustments in poor metabolizers or with inhibitors. Kidney disease and Wilms’ tumor are not contraindications.

MOOD, BEHAVIOR MEDICATION SAFETY AND MANAGEMENT

First-line pharmacologic therapy for childhood obsessive-compulsive disorder (OCD) is a selective serotonin reuptake inhibitor (SSRI). Efficacy of SSRIs has been well demonstrated in multiple studies, although no individual SSRI has shown superiority over another.

• Three SSRIs—fluvoxamine, fluoxetine, and sertraline—are FDA-approved for treatment of children with OCD. The FDA-approved ages vary: sertraline is approved from 6 through 17 years, fluoxetine for ages 7 through 17, and fluvoxamine for ages 8 through 17. This means that for a 6-year-old child, sertraline is the most appropriate FDA-approved option. Notably, only fluvoxamine requires twice-daily dosing. Effectiveness of SSRIs is enhanced when combined with concurrent psychotherapy.

When treating an adolescent with depression who is taking multiple medications for chronic conditions, careful selection of an SSRI is important to minimize drug-drug interactions. Among SSRIs, escitalopram is the best choice in this scenario because it has the least impact on the CYP450 enzyme system. Escitalopram is metabolized by multiple pathways, primarily CYP3A4 and CYP2C19, but inhibition of either enzyme does not significantly change its clearance. It does not significantly inhibit CYP2D6 in laboratory studies, although clinical experience suggests a modest effect, so caution is still advised with CYP2D6 substrates. This makes escitalopram especially useful in patients requiring polypharmacy.

Two SSRIs, fluoxetine and escitalopram, have FDA approval for the treatment of major depressive disorder (MDD) in pediatric patients. Fluoxetine was the first SSRI to be approved in the U.S. in 1988 and later received pediatric approval for children aged 8 through 17. It is also available in combination with olanzapine (Symbyax) for depressive episodes associated with Bipolar I disorder in children 10 through 17. Escitalopram also has approval for MDD in pediatric populations.

Second-generation antipsychotics (SGAs) are commonly prescribed in children with severe psychiatric disorders, but they are associated with significant risks. One of the most concerning is weight gain, which can lead to metabolic complications and long-term health consequences. Among SGAs, olanzapine has the highest likelihood of causing weight gain, followed by quetiapine, then risperidone, with aripiprazole being the least likely of the four to cause this adverse effect. Pediatric primary care providers play an important role in monitoring for these effects, even when the medications are initiated by subspecialists.

Another serious adverse effect of SGAs is acute dystonia, a painful condition involving sustained muscle contractions that may affect the face, neck, trunk, or extremities. This reaction typically occurs within days of starting or increasing the dose of an antipsychotic. In a school-aged child recently started on risperidone who presents with acute dystonia, the first-line treatments are benztropine (Cogentin) or diphenhydramine. These agents provide relief through anticholinergic mechanisms. Intravenous administration is preferred for severe reactions, while oral therapy can be used for milder cases. Diazepam may be considered only in refractory cases.

For children and adolescents with comorbid depression and ADHD, bupropion may be considered, although it does not have FDA approval in pediatrics. Bupropion is structurally similar to phenylethylamine, the chemical backbone of many stimulants, which gives it potential advantages for patients with both ADHD and depression. It is available in immediate- and extended-release formulations, though the immediate-release form is only available generically. Because bupropion inhibits reuptake of dopamine and norepinephrine but not serotonin, its mechanism differs from SSRIs.

Monitoring of bupropion should include weight, suicidality, and blood pressure. Bupropion carries a U.S. boxed warning regarding suicidal thoughts and behaviors, making ongoing psychiatric monitoring essential. Blood pressure should be measured at baseline and periodically thereafter, as the drug can increase blood pressure and, in some cases, heart rate. Weight changes—either gain or loss—can occur and should be tracked regularly. While serial electrocardiograms are not indicated, patients with hypertension or cardiac risk factors warrant special caution.

A child with obesity and bipolar disorder being treated with ziprasidone (Geodon), clinicians must be aware of important precautions. Ziprasidone carries warnings for QT interval prolongation, which can predispose patients to arrhythmias, as well as for neuroleptic malignant syndrome (NMS), a rare but life-threatening complication. Careful monitoring for cardiac and systemic side effects is critical when prescribing this medication.

Key Summary

• Childhood OCD: First-line treatment is an SSRI. FDA approvals include sertraline (ages 6+), fluoxetine (ages 7+), and fluvoxamine (ages 8+). Psychotherapy enhances outcomes.
• Pediatric Depression: Fluoxetine and escitalopram are FDA-approved. Escitalopram is preferred in polypharmacy due to fewer CYP450 interactions.
• SGAs: Major risk is weight gain, ranked from most to least likely: olanzapine > quetiapine > risperidone > aripiprazole. Acute dystonia may occur and is best treated with benztropine or diphenhydramine.
• Bupropion: Used off-label for comorbid ADHD and depression. Requires monitoring of blood pressure, weight, and suicidality due to cardiovascular and psychiatric risks.
• Ziprasidone: Important precautions include QT interval prolongation and neuroleptic malignant syndrome.

ADDITIONAL SAFETY AND MANAGEMENT

Ziprasidone (Geodon) is a second-generation antipsychotic (SGA) that has FDA-approved indications for adults with bipolar disorder and schizophrenia. While it has no pediatric FDA-approved indications, it is frequently used off-label for several conditions in children and adolescents, including acute agitation in schizophrenia, irritability associated with autism and pervasive developmental disorder, bipolar disorder, Tourette’s syndrome, and tic disorder.

Despite its therapeutic potential, ziprasidone carries several important warnings and precautions. The most significant is QT prolongation, which can increase the risk of arrhythmias. Because of this, ziprasidone is contraindicated in individuals with a history of QT prolongation or when taken concurrently with other medications known to prolong QT intervals. It should also be avoided in patients with bradycardia, hypokalemia, or hypomagnesemia. Another rare but potentially fatal adverse effect is neuroleptic malignant syndrome (NMS), a complex of hyperpyrexia, muscle rigidity, altered mental status, and autonomic instability reported with antipsychotics. Ziprasidone has also been associated with severe cutaneous adverse reactions such as drug reaction with eosinophilia and systemic symptoms (DRESS) and Stevens-Johnson syndrome. Other risks include tardive dyskinesia, hyperglycemia, dyslipidemia, diabetes mellitus, agranulocytosis, seizures, and suicidality.

Monitoring during ziprasidone therapy should be comprehensive. Baseline and ongoing assessments for metabolic abnormalities are recommended, including weight, body mass index (BMI), waist circumference, fasting lipids, and fasting glucose. Some experts advise routine electrocardiogram (ECG) monitoring, with discontinuation of ziprasidone if the QTc interval exceeds 500 milliseconds. Additional recommendations include monitoring complete blood counts as well as serum potassium and magnesium, particularly in patients at risk of electrolyte disturbances.

In contrast to antipsychotic management, an adolescent with mild depression managed with cognitive-based therapy may inquire about over-the-counter sleep aids such as melatonin. Melatonin is a hormone naturally secreted by the pineal gland in response to darkness to regulate circadian rhythm and sleep-wake cycles. Supplemental melatonin is available in both synthetic and animal-derived forms, though natural formulations derived from animal pineal glands are not recommended due to safety concerns.

In the United States, melatonin is sold over-the-counter as a dietary supplement, meaning it is not subject to the strict regulatory standards applied to prescription medications. In many other countries, including Canada, the United Kingdom, the European Union, and Australia, melatonin is only available by prescription. Evidence supports its effectiveness in reducing sleep onset latency in adults, and although pediatric data are more limited, some benefits have been demonstrated in children with ADHD, autism, and related conditions.

Melatonin is generally considered safe for short-term use, typically over days to weeks. Importantly, it can improve sleep quality with the first dose, and repeated nightly dosing is not necessary to achieve an initial effect. However, long-term use is not recommended, since there is insufficient evidence regarding long-term efficacy and safety in children or adults.

Key Summary

• Ziprasidone (Geodon): FDA-approved in adults for bipolar disorder and schizophrenia; used off-label in pediatrics for agitation, autism-related irritability, bipolar disorder, Tourette’s, and tic disorder.
• Risks/Warnings: QT prolongation, NMS, severe skin reactions (DRESS, Stevens-Johnson), tardive dyskinesia, metabolic effects, agranulocytosis, seizures, suicidality. Contraindicated with QT prolongation, bradycardia, hypokalemia, or hypomagnesemia.
• Monitoring: Weight, BMI, waist circumference, fasting glucose, lipids, CBC, electrolytes, and ECG with discontinuation if QTc > 500 ms.
• Melatonin: Naturally secreted hormone regulating circadian rhythm; available OTC in the U.S. but prescription-only in many countries.
• Evidence: Effective for reducing sleep latency in adults, limited but supportive pediatric data (especially in ADHD and autism).
• Safety: Short-term use considered safe; works on first dose; long-term use not recommended due to insufficient safety data.

This information is drawn from the Pediatric Nursing Certification Board (PNCB) reference materials, which provide evidence-based guidance for pediatric primary care certification and practice. The PNCB outlines both FDA-approved uses and common off-label practices for psychiatric medications in children, emphasizing safety considerations, contraindications, and monitoring requirements.

–PNCB

An Overview of Obtaining the Certification

The Pediatric Primary Care Mental Health Specialist (PMHS) certification—administered by the Pediatric Nursing Certification Board—validates the expertise of advanced practice nurses (NPs and CNSs) in identifying, intervening, and collaborating on behavioral and mental health concerns in children and adolescents (PNCB).

Eligibility and Exam Pathways

To be eligible for the PMHS exam, candidates must hold:

• A current, active, unrestricted APRN license, and
• A foundational certification such as PNP-PC, FNP, PMHNP-BC, or PMHCNS-BC (PNCB).

PNCB offers three pathways to fulfill eligibility requirements:

1. Traditional: 30 hours of pediatric behavioral health CE/CME or one 2-credit graduate course, plus 2,000 hours of pediatric developmental/behavioral/mental health (DBMH) clinical practice in the past 5 years.
2. Faculty Pathway: 1,000 hours of pediatric DBMH clinical practice and 10 points from teaching, precepting, scholarly activity, CE/CME, or academic credit.
3. Specialty Program Pathway: Completion of an approved program (e.g., Duke PBMH, KySS, Almost Home Kids, REACH PPP) plus 1,000 hours of pediatric DBMH clinical practice (PNCB).

Exam Structure and Preparation

The PMHS exam consists of 150 multiple-choice questions (125 scored, 25 unscored) across key content areas, including mental health promotion, evaluation, diagnostic decision-making, management, and professional role. It is administered in either in-person ProMetric centers or via secure live remote proctoring (PNCB).

Candidates are required to complete PNCB’s free “Ethics in Testing: A Personal Responsibility” CE module before submitting their application (PNCB). Study resources include a readiness checklist, test blueprint/content outline, recorded webinars, practice questions, and recommended clinical and psychopharmacology CE through PNCB and other trusted sources (PNCB).

Recertification Requirements

PMHS certification must be renewed annually between November 1 and January 31 before your credential expiration. Recertification includes:

• Maintaining an active APRN license and foundational NP/CNS certification.
• Completing at least 15 contact hours/year of pediatric DBMH CE, with a total of 30 pediatric psychopharmacology contact hours over the 7-year cycle (PNCB).

Value and Role of PMHS Credential

The PMHS credential builds on NP and CNS roles by formally recognizing advanced competency in behavioral health assessment, diagnosis, and management. It aligns with national care standards and fills critical gaps in pediatric mental health access. Having PMHS certification can boost clinical confidence, credibility, and professional recognition, especially for providers working in settings such as pediatric primary care, school-based clinics, or developmental specialty services (PNCB).

📌 Quick Reference at a Glance

• Eligible Roles: PNP-PC, FNP, PMHNP-BC, PMHCNS-BC
• 3 Pathways: Traditional, Faculty, Specialty Program
• Exam: 150 MCQs; offered in‐person or remotely
• Prep Requirements: Ethics module, readiness checklist, content outline, optional webinars & practice test
• Recertification Cycle: Annual renewal, DBMH CE and psychopharm hours over 7 years